[Targeted therapies and radiotherapy].
Targeted therapies are at this moment the subject of an intensive research program. Their action is, however, for most of them, cytostatic, and their combination with classical cytotoxic approaches, as radiotherapy, is logical. A lot of experimental data are now available, regarding interactions between radiations and EGF-receptor inhibitors, antiangiogenic therapies, farneysltransferase inhibitors and cell cycle inhibitors. These experimental results are reviewed, and possible mechanisms of interactions are discussed. Preliminary clinical results are reported and criticized. In conclusion, the combination of radiotherapy and targeted therapies seems a promising approach, particularly with the inhibitors of the EGFR pathway and anti-vascular treatments, and require the continuation and intensification of the clinical trials.
Hennequin
Christophe
C
Service de cancérologie-radiothérapie, hôpital Saint-Louis, AP-HP, 1 avenue Claude-Vellefaux, 75010 Paris. christophe.hennequin@sls.ap-hop-paris.fr
Giocanti
Nicole
N
Favaudon
Vincent
V
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D003131:Combined Modality Therapy / Q000379:methods*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D051231:Farnesyltranstransferase; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases